Compare VIAV & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIAV | CORT |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | VIAV | CORT |
|---|---|---|
| Price | $36.20 | $113.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $32.66 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 3.5M | 823.3K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | ★ $1,518,300,000.00 | $761,407,000.00 |
| Revenue This Year | $37.78 | $26.08 |
| Revenue Next Year | $10.64 | $26.98 |
| P/E Ratio | ★ N/A | $1,224.56 |
| Revenue Growth | ★ 40.03 | 12.79 |
| 52 Week Low | $12.05 | $28.66 |
| 52 Week High | $60.43 | $126.38 |
| Indicator | VIAV | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 52.88 |
| Support Level | $34.83 | $108.25 |
| Resistance Level | $39.06 | $124.30 |
| Average True Range (ATR) | 1.82 | 5.29 |
| MACD | 0.03 | -0.76 |
| Stochastic Oscillator | 45.86 | 61.04 |
Viavi Solutions Inc is a world-wide leader in test and measurement and optical technologies. Its test and measurement, and resilient Position, Navigation and Timing (PNT) solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, it develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets. The company's segments are Network and Service Enablement (NSE); and Optical Security and Performance Products (OSP). Majority of revenue comes from NSE segment. It has presence in Americas, Asia-Pacific, and EMEA. Majority of revenue is from America.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.